Showing 113 of 113on this page. Filters & sort apply to loaded results; URL updates for sharing.113 of 113 on this page
GFT505 attenuated hepatic lipid accumulation and the expression of ...
GFT505 attenuated hepatic steatosis, inflammation and fibrosis in ...
(PDF) GFT505 reverses NASH pathology, obesity and insulin resistance in ...
GFT505 923978-27-2 - ChemicalBook
Effect of GFT505 on the genes expression of PPAR signaling pathway and ...
GFT505 « New Drug Approvals
Effect of GFT505 on human skeletal muscle gene expression. Gene (mRNA ...
GFT505 Derivatives Ameliorate Alcohol-Induced Hepatic Steatosis and ...
GENFIT: GFT505 treatment prevents evolution to cirrhosis
Metabolic and anthropometric parameters after GFT505 or placebo ...
Elafibranor | GFT505 | PPAR α/δ agonist | Axon 2727 | Axon Medchem
Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 ...
(PDF) Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 ...
GFT505 - EIE CHEMICALS
Elafibranor | 923978-27-2 | AbMole | GFT505
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 ...
(PDF) Effects of the New Dual PPAR / Agonist GFT505 on Lipid and ...
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose ...
GFT505 | PPAR | TargetMol
Elafibranor (GFT505) | CAS NO.:923978-27-2 | GlpBio
新型GFT505衍生物的设计、合成及体内外抗NASH效果评价,European Journal of Medicinal Chemistry ...
PPT - Treating NASH with Fibrosis PowerPoint Presentation, free ...
Elafibranor (GFT505) | C22H24O4S | CID 75988815 - PubChem
elafibranor molecule, molecular structures, gft505, 3d model ...
Novel Peroxisome Proliferator Activated Receptor–α Agonists - American ...
Good Price CAS 923978-27-2 | Elafibranor(GFT505) for Sale - Quotation ...
Elafibranor(GFT505) 923978-27-2 wiki
Hepatoprotective effects of the dual peroxisome proliferator‐activated ...
Elafibranor(GFT505) | 923978-27-2
GFT505(依非兰诺) - ChemicalBook
The pharmacodynamic and differential gene expression analysis of PPAR α ...
Elafibranor (Standard) (GFT505 (Standard)) | PPARα/δ Agonist ...
PPT - Faculty of Pharmacy, Lille 2 _ March 2009 PowerPoint Presentation ...
Chemical structures of PPARα agonists. | Download Scientific Diagram
GFT505(824932-88-9) 1H NMR spectrum
GFT505; elafibranor E
dChanges in metabolic parameters. Least squares (ls) means changes in ...
Figure 1 from The dual peroxisome proliferator-activated receptor alpha ...
Hepatic and whole-body glucose metabolism during the two-step ...
依非兰诺_密度_沸点_分子量_依非兰诺CAS号【824932-88-9】_化源网
Elafibranor | PPAR | TargetMol
The dual peroxisome proliferator-activated receptor alpha/delta agonist ...
(PDF) The pharmacodynamic and differential gene expression analysis of ...
Iqirvo|Elafibranor|GFT505——药研档案
GFT 505, Elafibranor, элафибранор , إيلافيبرانور , 依非兰诺 « New Drug ...
E-Z-Elafibranor-E-Z-GFT505-生命科学试剂-MCE.docx - 人人文库
Elafibranor (GFT505) | PPARα/δ激动剂 | MCE
Elafibranor (GFT 505) , ≧98.0% | PPAR Agonist | CAS 923978-27-2 | Sun ...
Elafibranor « New Drug Approvals
좋은 가격 CAS 923978-27-2|Elafibranor(GFT505) 판매용 - 견적 - ALFA CHEMICAL
Metabolism of 2024 FDA Approved Small Molecules
近十年来首个获批治疗原发性胆汁性胆管炎药物Elafibranor的制备路线 - 知乎
Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary
Comparative Bioavailability - Gender Effect - Single and Multiple ...
如何理解肝脏纤维化疾病?常见的肝脏纤维化模型有哪些?_GemPharmatech
téléchargez le pdf - Le Journal de l`Intro
GRAPHIC
190404 Physiogenex_nashm|実験動物の生産・販売、実験動物用飼料の製造・販売の日本クレア株式会社
Design, synthesis, and biological evaluation of novel dual PPARα/δ ...
依非兰诺 824932-88-9 - ChemicalBook
Genfit : Cession précoce des droits du GFT505, ou levée de fonds ...
190404 Physiogenex_nashh|実験動物の生産・販売、実験動物用飼料の製造・販売の日本クレア株式会社
抑制剂-升德医药
Development of Heterocyclic PPAR Ligands for Potential Therapeutic ...
Macroscopic changes of the liver and changes in the expression of genes ...
PPT - How profitable is it to invest in NASH market? PowerPoint ...